Loading...

Fund Overview

Fund Size

Fund Size

₹271 Cr

Expense Ratio

Expense Ratio

2.39%

ISIN

ISIN

INF03VN01878

Minimum SIP

Minimum SIP

₹500

Exit Load

Exit Load

1.00%

Inception Date

Inception Date

06 Feb 2024

About this fund

This fund has been in existence for 1 years, 1 months and 22 days, having been launched on 06-Feb-24.
As of 27-Mar-25, it has a Net Asset Value (NAV) of ₹12.75, Assets Under Management (AUM) of 271.36 Crores, and an expense ratio of 2.39%.
  • WhiteOak Capital Pharma and Healthcare Fund Regular Growth has given a CAGR return of 23.82% since inception.
  • The fund's asset allocation comprises around 92.66% in equities, 0.00% in debts, and 7.34% in cash & cash equivalents.
  • You can start investing in WhiteOak Capital Pharma and Healthcare Fund Regular Growth with a SIP of ₹500 or a Lumpsum investment of ₹500.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+28.94%

+17.95% (Cat Avg.)

Since Inception

+23.82%

(Cat Avg.)

Portfolio Summaryas of 28th February 2025

Equity251.44 Cr92.66%
Others19.92 Cr7.34%

Top Holdings

All Holdings

Equity

Debt & Others

NameType sortAmount sortHoldings sort
Sun Pharmaceuticals Industries LtdEquity29.62 Cr10.92%
Cipla LtdEquity21.9 Cr8.07%
Max Healthcare Institute Ltd Ordinary SharesEquity20.1 Cr7.41%
Divi's Laboratories LtdEquity19.07 Cr7.03%
Lupin LtdEquity14.8 Cr5.45%
Fortis Healthcare LtdEquity10.15 Cr3.74%
Clearing Corporation Of India LtdCash - Repurchase Agreement9.56 Cr3.52%
Torrent Pharmaceuticals LtdEquity9.33 Cr3.44%
Krishna Institute of Medical Sciences LtdEquity8.85 Cr3.26%
Mankind Pharma LtdEquity7.54 Cr2.78%
Apollo Hospitals Enterprise LtdEquity6.84 Cr2.52%
Laurus Labs LtdEquity6.41 Cr2.36%
Ipca Laboratories LtdEquity6.17 Cr2.27%
Abbott India LtdEquity5.91 Cr2.18%
Ajanta Pharma LtdEquity5.89 Cr2.17%
Piramal Pharma LtdEquity5.47 Cr2.02%
J.B. Chemicals & Pharmaceuticals LtdEquity5.02 Cr1.85%
Poly Medicure LtdEquity4.77 Cr1.76%
Biocon LtdEquity4.77 Cr1.76%
GlaxoSmithKline Pharmaceuticals LtdEquity4.72 Cr1.74%
Global Health LtdEquity4.14 Cr1.53%
Jupiter Life Line Hospitals LtdEquity3.78 Cr1.39%
Vijaya Diagnostic Centre LtdEquity3.56 Cr1.31%
Neuland Laboratories LimitedEquity3.53 Cr1.30%
Rainbow Childrens Medicare LtdEquity3.32 Cr1.22%
Eris Lifesciences Ltd Registered ShsEquity3.24 Cr1.19%
Ami Organics LtdEquity3.11 Cr1.14%
Navin Fluorine International LtdEquity3.09 Cr1.14%
91 Days Tbill Red 08-05-2025Bond - Gov't/Treasury2.96 Cr1.09%
Supriya Lifescience LtdEquity2.87 Cr1.06%
AstraZeneca Pharma India LtdEquity2.64 Cr0.97%
Strides Pharma Science LtdEquity2.63 Cr0.97%
Kovai Medical Center & Hospital LtdEquity2.58 Cr0.95%
RPG Life Sciences LtdEquity2.07 Cr0.76%
Thyrocare Technologies LtdEquity1.98 Cr0.73%
Laxmi Dental LtdEquity1.98 Cr0.73%
364 DTB 23052025Bond - Gov't/Treasury1.97 Cr0.73%
Blue Jet Healthcare LtdEquity1.83 Cr0.68%
Sai Life Sciences LtdEquity1.66 Cr0.61%
Net Receivables / (Payables)Cash1.65 Cr0.61%
SRF LtdEquity1.55 Cr0.57%
Sanofi Consumer Healthcare India LtdEquity1.52 Cr0.56%
Shaily Engineering Plastics LtdEquity1.22 Cr0.45%
Dr Agarwal'S Eye Hospital LtdEquity1.06 Cr0.39%
91 DTB 20032025Bond - Gov't/Treasury1 Cr0.37%
91 DTB 10042025Bond - Gov't/Treasury0.99 Cr0.37%
91 DTB 17042025Bond - Gov't/Treasury0.99 Cr0.37%
Zota Health Care LtdEquity0.72 Cr0.26%
91 Days Tbill Red 24-04-2025Bond - Gov't/Treasury0.5 Cr0.18%
364 DTB 13032025Bond - Gov't/Treasury0.2 Cr0.07%
91 DTB 28032025Bond - Gov't/Treasury0.1 Cr0.04%

Allocation By Market Cap (Equity)

Large Cap Stocks

29.45%

Mid Cap Stocks

32.59%

Small Cap Stocks

28.58%

Allocation By Credit Quality (Debt)

AAA

Other Allocation

Equity Sector

Debt & Others

SectorAmount sortHoldings sort
Healthcare238.93 Cr88.05%
Basic Materials7.42 Cr2.74%
Industrials1.55 Cr0.57%

Risk & Performance Ratios

Standard Deviation

This fund

--

Cat. avg.

16.58%

Lower the better

Sharpe Ratio

This fund

--

Cat. avg.

0.70

Higher the better

Sortino Ratio

This fund

--

Cat. avg.

1.18

Higher the better

Fund Managers

Piyush Baranwal

Piyush Baranwal

Since February 2024

Ramesh Mantri

Ramesh Mantri

Since February 2024

DP

Dheeresh Pathak

Since February 2024

AA

Ashish Agrawal

Since January 2025

Additional Scheme Detailsas of 28th February 2025

ISIN
INF03VN01878
Expense Ratio
2.39%
Exit Load
1.00%
Fund Size
₹271 Cr
Age
1 year 1 month
Lumpsum Minimum
₹500
Fund Status
Open Ended Investment Company
Benchmark
BSE Healthcare TR INR

Investment ObjectiveInvestment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

iconCapital Gains Taxation:

iconDividend Taxation:

info icon

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund nameExpense RatioExit LoadFund size
1Y
Motilal Oswal S&P BSE Healthcare ETF

Very High Risk

0.2%-₹25.63 Cr20.0%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Very High Risk

1.1%1.0%₹754.75 Cr13.4%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹754.75 Cr11.9%
Aditya Birla Sun Life Nifty Healthcare ETF

Very High Risk

0.2%-₹37.95 Cr15.9%
ITI Pharma and Healthcare Fund Direct Growth

Very High Risk

0.5%1.0%₹200.83 Cr19.0%
ITI Pharma and Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹200.83 Cr16.8%
Mirae Asset Healthcare Fund Direct Growth

Very High Risk

0.5%1.0%₹2441.13 Cr19.9%
Mirae Asset Healthcare Fund Regular Growth

Very High Risk

2.0%1.0%₹2441.13 Cr18.2%
Nippon India Nifty Pharma ETF

Very High Risk

0.2%-₹809.18 Cr13.8%
Axis NIFTY Healthcare ETF

Very High Risk

0.3%-₹17.44 Cr15.8%

Risk Level

Your principal amount will be at Very High Risk

Very High Risk

Take control of your wealth

Track and Analyse all your investments with Wealth Monitor

qr

Rated ★ 4.3+ on

playstoreappstore

Still got questions?
We're here to help.

The NAV of WhiteOak Capital Pharma and Healthcare Fund Regular Growth, as of 27-Mar-2025, is ₹12.75.
The fund's allocation of assets is distributed as 92.66% in equities, 0.00% in bonds, and 7.34% in cash and cash equivalents.
The fund managers responsible for WhiteOak Capital Pharma and Healthcare Fund Regular Growth are:-
  1. Piyush Baranwal
  2. Ramesh Mantri
  3. Dheeresh Pathak
  4. Ashish Agrawal

Fund Overview

Fund Size

Fund Size

₹271 Cr

Expense Ratio

Expense Ratio

2.39%

ISIN

ISIN

INF03VN01878

Minimum SIP

Minimum SIP

₹500

Exit Load

Exit Load

1.00%

Inception Date

Inception Date

06 Feb 2024

Risk Level

Your principal amount will be at Very High Risk

Very High Risk

About this fund

This fund has been in existence for 1 years, 1 months and 22 days, having been launched on 06-Feb-24.
As of 27-Mar-25, it has a Net Asset Value (NAV) of ₹12.75, Assets Under Management (AUM) of 271.36 Crores, and an expense ratio of 2.39%.
  • WhiteOak Capital Pharma and Healthcare Fund Regular Growth has given a CAGR return of 23.82% since inception.
  • The fund's asset allocation comprises around 92.66% in equities, 0.00% in debts, and 7.34% in cash & cash equivalents.
  • You can start investing in WhiteOak Capital Pharma and Healthcare Fund Regular Growth with a SIP of ₹500 or a Lumpsum investment of ₹500.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+28.94%

+17.95% (Cat Avg.)

Since Inception

+23.82%

(Cat Avg.)

Portfolio Summaryas of 28th February 2025

Equity251.44 Cr92.66%
Others19.92 Cr7.34%

Top Holdings

All Holdings

Equity

Debt & Others

NameType sortAmount sortHoldings sort
Sun Pharmaceuticals Industries LtdEquity29.62 Cr10.92%
Cipla LtdEquity21.9 Cr8.07%
Max Healthcare Institute Ltd Ordinary SharesEquity20.1 Cr7.41%
Divi's Laboratories LtdEquity19.07 Cr7.03%
Lupin LtdEquity14.8 Cr5.45%
Fortis Healthcare LtdEquity10.15 Cr3.74%
Clearing Corporation Of India LtdCash - Repurchase Agreement9.56 Cr3.52%
Torrent Pharmaceuticals LtdEquity9.33 Cr3.44%
Krishna Institute of Medical Sciences LtdEquity8.85 Cr3.26%
Mankind Pharma LtdEquity7.54 Cr2.78%
Apollo Hospitals Enterprise LtdEquity6.84 Cr2.52%
Laurus Labs LtdEquity6.41 Cr2.36%
Ipca Laboratories LtdEquity6.17 Cr2.27%
Abbott India LtdEquity5.91 Cr2.18%
Ajanta Pharma LtdEquity5.89 Cr2.17%
Piramal Pharma LtdEquity5.47 Cr2.02%
J.B. Chemicals & Pharmaceuticals LtdEquity5.02 Cr1.85%
Poly Medicure LtdEquity4.77 Cr1.76%
Biocon LtdEquity4.77 Cr1.76%
GlaxoSmithKline Pharmaceuticals LtdEquity4.72 Cr1.74%
Global Health LtdEquity4.14 Cr1.53%
Jupiter Life Line Hospitals LtdEquity3.78 Cr1.39%
Vijaya Diagnostic Centre LtdEquity3.56 Cr1.31%
Neuland Laboratories LimitedEquity3.53 Cr1.30%
Rainbow Childrens Medicare LtdEquity3.32 Cr1.22%
Eris Lifesciences Ltd Registered ShsEquity3.24 Cr1.19%
Ami Organics LtdEquity3.11 Cr1.14%
Navin Fluorine International LtdEquity3.09 Cr1.14%
91 Days Tbill Red 08-05-2025Bond - Gov't/Treasury2.96 Cr1.09%
Supriya Lifescience LtdEquity2.87 Cr1.06%
AstraZeneca Pharma India LtdEquity2.64 Cr0.97%
Strides Pharma Science LtdEquity2.63 Cr0.97%
Kovai Medical Center & Hospital LtdEquity2.58 Cr0.95%
RPG Life Sciences LtdEquity2.07 Cr0.76%
Thyrocare Technologies LtdEquity1.98 Cr0.73%
Laxmi Dental LtdEquity1.98 Cr0.73%
364 DTB 23052025Bond - Gov't/Treasury1.97 Cr0.73%
Blue Jet Healthcare LtdEquity1.83 Cr0.68%
Sai Life Sciences LtdEquity1.66 Cr0.61%
Net Receivables / (Payables)Cash1.65 Cr0.61%
SRF LtdEquity1.55 Cr0.57%
Sanofi Consumer Healthcare India LtdEquity1.52 Cr0.56%
Shaily Engineering Plastics LtdEquity1.22 Cr0.45%
Dr Agarwal'S Eye Hospital LtdEquity1.06 Cr0.39%
91 DTB 20032025Bond - Gov't/Treasury1 Cr0.37%
91 DTB 10042025Bond - Gov't/Treasury0.99 Cr0.37%
91 DTB 17042025Bond - Gov't/Treasury0.99 Cr0.37%
Zota Health Care LtdEquity0.72 Cr0.26%
91 Days Tbill Red 24-04-2025Bond - Gov't/Treasury0.5 Cr0.18%
364 DTB 13032025Bond - Gov't/Treasury0.2 Cr0.07%
91 DTB 28032025Bond - Gov't/Treasury0.1 Cr0.04%

Allocation By Market Cap (Equity)

Large Cap Stocks

29.45%

Mid Cap Stocks

32.59%

Small Cap Stocks

28.58%

Allocation By Credit Quality (Debt)

AAA

Other Allocation

Equity Sector

Debt & Others

SectorAmount sortHoldings sort
Healthcare238.93 Cr88.05%
Basic Materials7.42 Cr2.74%
Industrials1.55 Cr0.57%

Risk & Performance Ratios

Standard Deviation

This fund

--

Cat. avg.

16.58%

Lower the better

Sharpe Ratio

This fund

--

Cat. avg.

0.70

Higher the better

Sortino Ratio

This fund

--

Cat. avg.

1.18

Higher the better

Fund Managers

Piyush Baranwal

Piyush Baranwal

Since February 2024

Ramesh Mantri

Ramesh Mantri

Since February 2024

DP

Dheeresh Pathak

Since February 2024

AA

Ashish Agrawal

Since January 2025

Additional Scheme Detailsas of 28th February 2025

ISIN
INF03VN01878
Expense Ratio
2.39%
Exit Load
1.00%
Fund Size
₹271 Cr
Age
1 year 1 month
Lumpsum Minimum
₹500
Fund Status
Open Ended Investment Company
Benchmark
BSE Healthcare TR INR

Investment ObjectiveInvestment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

iconCapital Gains Taxation:

iconDividend Taxation:

info icon

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund nameExpense RatioExit LoadFund size
1Y
Motilal Oswal S&P BSE Healthcare ETF

Very High Risk

0.2%-₹25.63 Cr20.0%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Very High Risk

1.1%1.0%₹754.75 Cr13.4%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹754.75 Cr11.9%
Aditya Birla Sun Life Nifty Healthcare ETF

Very High Risk

0.2%-₹37.95 Cr15.9%
ITI Pharma and Healthcare Fund Direct Growth

Very High Risk

0.5%1.0%₹200.83 Cr19.0%
ITI Pharma and Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹200.83 Cr16.8%
Mirae Asset Healthcare Fund Direct Growth

Very High Risk

0.5%1.0%₹2441.13 Cr19.9%
Mirae Asset Healthcare Fund Regular Growth

Very High Risk

2.0%1.0%₹2441.13 Cr18.2%
Nippon India Nifty Pharma ETF

Very High Risk

0.2%-₹809.18 Cr13.8%
Axis NIFTY Healthcare ETF

Very High Risk

0.3%-₹17.44 Cr15.8%

Still got questions?
We're here to help.

The NAV of WhiteOak Capital Pharma and Healthcare Fund Regular Growth, as of 27-Mar-2025, is ₹12.75.
The fund's allocation of assets is distributed as 92.66% in equities, 0.00% in bonds, and 7.34% in cash and cash equivalents.
The fund managers responsible for WhiteOak Capital Pharma and Healthcare Fund Regular Growth are:-
  1. Piyush Baranwal
  2. Ramesh Mantri
  3. Dheeresh Pathak
  4. Ashish Agrawal
close

Get your portfolio reviewed by experts

qr

Track all your investments in one place

Download Wealth Monitor App

cross
wm logo

Track and monitor all
your investments